Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

L'Efficacité de la supplémentation en probiotiques sur le stress et l'anxiété (PROfoS)

22 septembre 2026 mis à jour par: Nordic Biotic Sp. z o.o.

L'Efficacité de la Complémentation en Probiotiques sur le Stress et l'Anxiété - une Étude Interventionnelle Randomisée, Contrôlée par Placebo chez des Étudiants en Bonne Santé Pendant la Période d'Examens.

This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of an 8-week probiotic supplementation (Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 in total daily dose 1 × 10¹⁰ CFU or matching placebo) in reducing perceived stress and anxiety, and improvement related psychological parameters in healthy university students during the examination period. The primary outcome is the change in Perceived Stress Scale (PSS-10) score at week 5 and week 8 of interevention compared to placebo. The secondary outcomes are the changes in DASS-21 subscales (Stress, Anxiety, Depression), State-Trait Anxiety Inventory - State version scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms (Likert scale) and incidence of adverse events during the 8-week lasting interventional study.

Aperçu de l'étude

Description détaillée

The gut-brain axis enables bidirectional communication between the gastrointestinal tract and the central nervous system. Emerging evidence suggests that selected probiotic strains (psychobiotics) may modulate stress responses and emotional regulation. University examination periods constitute a predictable model of transient psychological stress in otherwise healthy individuals.

This study investigates whether daily supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 reduces perceived stress and improves related psychological parameters in healthy students exposed to exam-related stress. Two hundred male and female students aged 18-40 years with at least moderate stress and mild anxiety, but without clinical depression, will be enrolled at the Medical University of Lublin, Poland. After providing written informed consent and confirming eligibility criteria, participants will be randomized in a 1:1 ratio to receive either a probiotic formulation containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ colony-forming units) or a matching placebo.

The investigational product and placebo will be identical in appearance and administered orally once daily (two capsules) for 8 weeks. Randomization will be computer-generated, and both participants and investigators will remain blinded to treatment allocation throughout the study. The intervention will begin approximately six weeks before the first scheduled academic examination. Study assessments will be conducted at baseline, at week 5 (approximately one week before the first examination), and at week 8 (±3 days before a subsequent examination). Psychological and functional parameters will be collected using validated self-report instruments administered electronically, with selected assessments performed during on-site visits. Participants will be asked to maintain their usual diet, physical activity, and caffeine intake during the study period. Safety and tolerability will be monitored throughout the intervention, and adverse events will be recorded using an electronic reporting system with daily reminders.

The study is powered to detect clinically meaningful differences between groups in perceived stress levels and will be analyzed using appropriate covariance-based statistical models adjusted for baseline values and relevant covariates. All participant data will be coded to ensure confidentiality and handled in accordance with applicable data protection regulations.

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Bożena Cukrowska, Prof., MD, PhD
  • Numéro de téléphone: 609447892
  • E-mail: bc@nordicbiotic.com

Lieux d'étude

      • Lublin, Pologne
        • Recrutement
        • University of Lublin, Faculty of Health Sciences
        • Contact:
        • Chercheur principal:
          • Emilia Majsiak, Prof., PhD
        • Sous-enquêteur:
          • Renata Markiewicz, PhD
        • Sous-enquêteur:
          • Mariusz Wysokiński, Prof., PhD
        • Sous-enquêteur:
          • Wiesław Fidecki, Prof. PhD
        • Sous-enquêteur:
          • Kinga Zdunek, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female students aged 18-40 years
  • At least moderate stress (DASS-21 Stress score ≥10)
  • Mild anxiety (DASS-21 Anxiety score 6-13)
  • No clinical depression (DASS-21 Depression score ≤9)
  • Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study
  • Written informed consent

Exclusion Criteria:

  • Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)
  • Known food allergies, immunodeficiency disorders, or immunosuppressive treatment
  • Antibiotic use within 4 weeks prior to screening
  • Any psychiatric illness within the past 5 years
  • Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)
  • Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening
  • Pregnancy, breastfeeding, or plans to become pregnant during the study
  • Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening
  • Heavy caffeine consumption (>4 cups of 300 mL coffee per day)
  • Drug or alcohol addiction or regular use of recreational drugs
  • Smoking more than 10 cigarettes per day

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Probiotic

Two capsules containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 will be administered orally once daily (total daily dose of 1 × 10¹⁰ colony-forming units) for 8 weeks.

Lactobacillus plantarum LP140 and Bifidobacterium breve BB010

Comparateur placebo: Placebo

Maltodextrin will be used as a placebo. The placebo capsules will be identical in appearance to the probiotic capsules and will be administered orally once daily (two capsules) for 8 weeks.

Maltodextrin

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in perceived stress score
Délai: Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo

Perceived stress will be assessed using the 10-Item Perceived Stress Scale (PSS-10), a validated questionnaire measuring the degree to which situations in one's life are appraised as stressful. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels (worse outcome). Changes in the total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in stress, anxiety and depression scores
Délai: Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.

Stress, anxiety, and depression will be assessed using the Depression Anxiety Stress Scales - 21 Items (DASS-21). The DASS-21 consists of three subscales (Depression, Anxiety, and Stress), each including 7 items. Scores for each subscale range from 0 to 42 after standard score multiplication, with higher scores indicating greater symptom severity (worse outcome). Changes in the Stress, Anxiety, and Depression subscale scores from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
Change in sleep quality score
Délai: Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire measuring sleep quality over the previous month. The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). Changes in the PSQI global score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
Change in sense of coherence score
Délai: Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.

Sense of coherence will be assessed using the Sense of Coherence Scale - 29 Items (SOC-29), a validated questionnaire measuring psychological resilience and the ability to cope with stress. The total score ranges from 29 to 203, with higher scores indicating a stronger sense of coherence (better outcome). Changes in the SOC-29 total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.
Change in state anxiety score
Délai: Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.

State anxiety will be assessed using the State-Trait Anxiety Inventory - State version (STAI-S), a validated questionnaire measuring the current level of anxiety. The STAI-S total score ranges from 20 to 80, with higher scores indicating higher levels of anxiety (worse outcome). Changes in the STAI-S total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
Change in severity of gastro-intestinal symptoms
Délai: Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo

The severitty of gastro-intestinal symptoms will be assessed with the use of 4-point Likert scale (0 - no symptom, 1 - weak, 2 - moderate, 4 - severe). The following symptoms will be assessed: abdominal pain, flatulence, nausea.

Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
Incidence of treatment-emergent adverse events (Safety and Tolerability)
Délai: From baseline through the 8-week intervention period.

Safety and tolerability will be assessed by monitoring the incidence of adverse events throughout the study. Adverse events will be self-reported by participants using an electronic reporting platform, which provides daily reminders for study product intake and allows participants to record any symptoms or adverse events experienced during the study period.

From baseline through the 8-week intervention period.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Emilia Majsiak, Prof. PhD, Medical University of Lublin

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 avril 2026

Achèvement primaire (Réel)

15 juillet 2026

Achèvement de l'étude (Estimé)

15 octobre 2026

Dates d'inscription aux études

Première soumission

10 mars 2026

Première soumission répondant aux critères de contrôle qualité

10 mars 2026

Première publication (Réel)

13 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner